Synthelabo Signs Deal With Texas Biotech

24 October 1994

Synthelabo has signed a collaborative agreement with Texas Biotechnology Corp to codevelop and market compounds to prevent reocclusion of blood vessels using antisense oligonucleotides and antagonists of fibroblast growth factors to inhibit proliferation of vascular smooth muscle cells.

Under the agreement, Synthelabo will receive an exclusive license to manufacture, use, and sell any products generated through the collaboration in Europe, the Middle East, Africa and the countries of the former Soviet Union. TBC retains marketing rights for these products in North America and Asia.

As part of the collaboration, Synthelabo invested $5 million in TBC stock and will pay an up-front licensing fee of $3 million. In addition, Synthelabo expects to pay TBC $3 million annually in research funding for three years, and has committed to further payments of up to L3 million per year for an additional six years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight